Live Breaking News & Updates on Biodrg

Stay updated with breaking news from Biodrg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln

An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals /CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease. ....

United States , Bhanvi Satija , Vertex Pharmaceuticals , Institute For Clinical , Thomson Reuters Trust Principles , Economic Review , David Rind , Biomarin Pharmaceutical , Thomson Reuters Trust , Rhpi Biopharma ,

US govt tells vaccine makers to price updated COVID shots reasonably

COVID vaccine makers should price their updated shots for the fall at a reasonable rate that would reflect the benefits they received through government investments, the U.S. Department of Health and Human Services (HHS) said on Thursday. ....

United States , Shinjini Ganguli , Shailesh Kuber , Bhanvi Satija , Access Program , Drug Administration , Us Department Of Health , Human Services , Thomson Reuters Trust Principles , Disease Control , Thomson Reuters Trust , Nrlin Ocov , Rhpi Public Health , Ef Business Future Of Health , Nrlpa Ohlt , Nrlpa Opub , Reuters Legal ,

Mark Cuban's online pharmacy set to launch Humira biosimilar

Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's biosimilar version of AbbVie Inc's blockbuster rheumatoid arthritis drug Humira, Cuban said on Wednesday. ....

David Holmes , Coherus Biosciences , Abbvie Inc , Thomson Reuters Trust Principles , Boehringer Ingelheim , Cuban Cost Plus Drugs , Plus Drugs , Cost Plus Drugs , Michael Erman , Thomson Reuters Trust ,

Clene's ALS drug shows reduction in disease indicator levels in trial

Clene said on Thursday its experimental amyotrophic lateral sclerosis (ALS) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial. ....

Krishna Chandra Eluri , Raghav Mahobe , Lou Gehrig , Thomson Reuters Trust Principles , Drug Administration , Krishna Chandra , Thomson Reuters Trust , Rsbi Regulatory Oversight , Rhpi Biopharma , Rhpi Regulatory ,